← All organizations

Glenmark Pharmaceuticals

For profitWebsite ↗

Also known as: GLENMARK | Glenmark Farmacêutica Ltda | GLENMARK GENERICS | Glenmark Pharamceuticals SA | Glenmark Pharmaceuticals | Glenmark Pharmaceutical S.A | Glenmark Pharmaceuticals Europe Ltd. (R&D) | Glenmark Pharmaceuticals Inc., USA | Glenmark Pharmaceuticals Ltd | Glenmark Pharmaceuticals Ltd. | Glenmark Pharmaceuticals Ltd. India | Glenmark Pharmaceuticals S.A. | GLENMARK PHARMS | GLENMARK PHARMS INC | GLENMARK PHARMS LTD | GLENMARK PHARMS SA | GLENMARK SPECIALTY | Glenmark Specialty S.A. | GLENMARK SPECLT

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 3

First clinical trial

First marketed drug

Last known activity

Apr 8, 2026

Timeline

1990s

Jan 1, 1997
Glenmark Pharmaceuticals— Founded

2010s

Apr 7, 2017
fenofibrate— Marketing Organization

2020s

Jan 13, 2022
mometasone— NDA Secondary Org

Drugs by trial phase (29 distinct, 31 trials)

Phase 3 (12 own, 0 via acquisition)

Phase 2 (9 own, 0 via acquisition)

Phase 1 (8 own, 0 via acquisition)

Recent trials (50)

NCT05878691Lead sponsorPhase 1Jun 28, 2022
NCT05878691Study directorPhase 1Jun 28, 2022
NCT05363202Lead sponsorPhase 3Apr 15, 2022
NCT05363202Study directorPhase 3Apr 15, 2022
NCT05599919CollaboratorPhase 3Nov 1, 2021
NCT03983395Lead sponsorPhase 1/Phase 2Jun 22, 2019
NCT03983395Study directorPhase 1/Phase 2Jun 22, 2019
NCT03731091Lead sponsorPhase 3Oct 31, 2018
NCT03731091Study directorPhase 3Oct 31, 2018
NCT03568162Lead sponsorPhase 2May 31, 2018
NCT03568162Study directorPhase 2May 31, 2018
NCT03463031Lead sponsorPhase 3Mar 16, 2018
NCT03463031Study directorPhase 3Mar 16, 2018
NCT03331523Lead sponsorPhase 3Oct 20, 2017
NCT03331523Study directorPhase 3Oct 20, 2017

Details

Founded: Mumbai, IN Jan 1, 1997
Last known activity: Apr 8, 2026